News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Bayer AG’s Inhaler Drug Gets Thumbs Up in Test
May 20, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
FRANKFURT, May 20 (Reuters) - Bayer's (BAYG.DE: Quote, Profile, Research) experimental inhaler drug looked set to become a hit after a study of the device that patients use to inhale the antibiotic showed promising results, analysts said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
Nektar Therapeutics
MORE ON THIS TOPIC
Phase 3
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
August 13, 2026
·
3 min read
·
Gabrielle Masson
Insights
The Italian inflection point: Clinical strength, culture and capital
August 13, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
·
3 min read
·
Annalee Armstrong
IPO
2026 IPO stock tracker: How newly public biotechs are performing
August 12, 2026
·
1 min read
·
Gabrielle Masson
